Alejandra Ortiz-Ruiz
Overview
Explore the profile of Alejandra Ortiz-Ruiz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
80
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez-Garcia A, Ancos-Pintado R, Garcia-Vicente R, Ortiz-Ruiz A, Arroyo A, Navarro M, et al.
Microbiome
. 2025 Feb;
13(1):56.
PMID: 40022244
Background: Gut microbiota-derived urolithins may influence multiple myeloma (MM) disease progression and treatment. We analyzed urolithins and their associated microbiota in a retrospective cohort of 45 patients with active MM...
2.
Bermejo-Pelaez D, Rueda Charro S, Garcia Roa M, Trelles-Martinez R, Bobes-Fernandez A, Soto M, et al.
Microsc Microanal
. 2024 Feb;
30(1):151-159.
PMID: 38302194
Analysis of bone marrow aspirates (BMAs) is an essential step in the diagnosis of hematological disorders. This analysis is usually performed based on a visual examination of samples under a...
3.
Munawar U, Zhou X, Prommersberger S, Nerreter S, Vogt C, Steinhardt M, et al.
Commun Biol
. 2023 Dec;
6(1):1299.
PMID: 38129580
The treatment landscape in multiple myeloma (MM) is shifting from genotoxic drugs to immunotherapies. Monoclonal antibodies, immunoconjugates, T-cell engaging antibodies and CART cells have been incorporated into routine treatment algorithms,...
4.
Morales M, Garcia-Vicente R, Rodriguez-Garcia A, Reyes-Palomares A, Vincelle-Nieto A, Alvarez N, et al.
Leukemia
. 2023 Jul;
37(8):1649-1659.
PMID: 37422594
Despite the approval of several drugs for AML, cytarabine is still widely used as a therapeutic approach. However, 85% of patients show resistance and only 10% overcome the disease. Using...
5.
Ruiz-Heredia Y, Ortiz-Ruiz A, Samur M, Garrido V, Rufian L, Sanchez R, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34202390
Many studies over the last 20 years have investigated the role of mitochondrial DNA (mtDNA) alterations in carcinogenesis. However, the status of the mtDNACN in MM and its implication in...
6.
Ortiz-Ruiz A, Ruiz-Heredia Y, Morales M, Aguilar-Garrido P, Garcia-Ortiz A, Valeri A, et al.
Cancers (Basel)
. 2021 Apr;
13(7).
PMID: 33916196
Mitochondria are involved in the development and acquisition of a malignant phenotype in hematological cancers. Recently, their role in the pathogenesis of multiple myeloma (MM) has been suggested to be...
7.
Carreras P, Gonzalez I, Gallardo M, Ortiz-Ruiz A, Morales M, Encinas J, et al.
Micromachines (Basel)
. 2021 Jan;
12(1).
PMID: 33467039
We previously reported a new approach for micromanipulation and encapsulation of human stem cells using a droplet-based microfluidic device. This approach demonstrated the possibility of encapsulating and culturing difficult-to-preserve primary...
8.
Rodriguez-Garcia A, Garcia-Vicente R, Morales M, Ortiz-Ruiz A, Martinez-Lopez J, Linares M
Antioxidants (Basel)
. 2020 Dec;
9(12).
PMID: 33271863
Among the different mechanisms involved in oxidative stress, protein carbonylation and lipid peroxidation are both important modifications associated with the pathogenesis of several diseases, including cancer. Hematopoietic cells are particularly...
9.
Carreras P, Gonzalez I, Gallardo M, Ortiz-Ruiz A, Martinez-Lopez J
Micromachines (Basel)
. 2020 Mar;
11(3).
PMID: 32121351
We previously reported a new approach for micromanipulation and encapsulation of human stem cells using a droplet-based microfluidic device We demonstrated the possibility of encapsulating and culturing difficult-to-preserve primary human...
10.
Morales M, Arenas A, Ortiz-Ruiz A, Leivas A, Rapado I, Rodriguez-Garcia A, et al.
Sci Rep
. 2019 Dec;
9(1):18630.
PMID: 31819100
FMS-like tyrosine kinase 3 (FLT3) is a key driver of acute myeloid leukemia (AML). Several tyrosine kinase inhibitors (TKIs) targeting FLT3 have been evaluated clinically, but their effects are limited...